[go: up one dir, main page]

TR200100622T2 - NAB1 ve NAB2'nin farmasötik kullanımları - Google Patents

NAB1 ve NAB2'nin farmasötik kullanımları

Info

Publication number
TR200100622T2
TR200100622T2 TR2001/00622T TR200100622T TR200100622T2 TR 200100622 T2 TR200100622 T2 TR 200100622T2 TR 2001/00622 T TR2001/00622 T TR 2001/00622T TR 200100622 T TR200100622 T TR 200100622T TR 200100622 T2 TR200100622 T2 TR 200100622T2
Authority
TR
Turkey
Prior art keywords
nab1
nab2
pharmaceutical uses
polypeptide
polypeptides
Prior art date
Application number
TR2001/00622T
Other languages
English (en)
Inventor
Braddock Martin
Jeffrey Campbell Callum
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200100622T2 publication Critical patent/TR200100622T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Bulus, insan dahil olmak üzere bir memelide yara iyilesmesi ile birlikte görülen hücre bozukluklarinin iyilestirilmesi için bir tibbi maddenin imalatinda, özellikle gen terapisinde, bir NAB1 yada NAB2 polipeptidi ya da bu polipeptidin biyolojik açidan aktif bir fragmaninin kullanimi ve bu polipeptidleri kodlayan nükleik asit moleküllerine iliskindir.
TR2001/00622T 1998-07-11 1999-07-09 NAB1 ve NAB2'nin farmasötik kullanımları TR200100622T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method

Publications (1)

Publication Number Publication Date
TR200100622T2 true TR200100622T2 (tr) 2001-10-22

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00622T TR200100622T2 (tr) 1998-07-11 1999-07-09 NAB1 ve NAB2'nin farmasötik kullanımları

Country Status (22)

Country Link
EP (1) EP1097200A1 (tr)
JP (1) JP2002520020A (tr)
KR (1) KR20010071832A (tr)
CN (1) CN1317045A (tr)
AP (1) AP2001002038A0 (tr)
AU (1) AU763713B2 (tr)
BR (1) BR9912018A (tr)
CA (1) CA2336805A1 (tr)
EA (1) EA200100028A1 (tr)
EE (1) EE200100020A (tr)
HR (1) HRP20010025A2 (tr)
HU (1) HUP0102835A3 (tr)
ID (1) ID27742A (tr)
IL (1) IL140533A0 (tr)
IS (1) IS5788A (tr)
NO (1) NO20010166L (tr)
NZ (1) NZ509174A (tr)
PL (1) PL345507A1 (tr)
SK (1) SK382001A3 (tr)
TR (1) TR200100622T2 (tr)
WO (1) WO2000003014A1 (tr)
YU (1) YU1901A (tr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
US6753321B2 (en) 2000-09-15 2004-06-22 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (en) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Nab proteins and their use in diagnostic and therapeutic applications in heart disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
CN1317045A (zh) 2001-10-10
KR20010071832A (ko) 2001-07-31
AU4791499A (en) 2000-02-01
BR9912018A (pt) 2006-01-31
NO20010166D0 (no) 2001-01-10
EP1097200A1 (en) 2001-05-09
NZ509174A (en) 2003-08-29
IS5788A (is) 2000-12-22
EE200100020A (et) 2002-06-17
IL140533A0 (en) 2002-02-10
PL345507A1 (en) 2001-12-17
CA2336805A1 (en) 2000-01-20
HUP0102835A3 (en) 2003-09-29
NO20010166L (no) 2001-03-06
AP2001002038A0 (en) 2001-03-31
SK382001A3 (en) 2001-09-11
AU763713B2 (en) 2003-07-31
EA200100028A1 (ru) 2001-08-27
YU1901A (sh) 2005-06-10
HUP0102835A2 (hu) 2001-11-28
ID27742A (id) 2001-04-26
WO2000003014A1 (en) 2000-01-20
JP2002520020A (ja) 2002-07-09
HRP20010025A2 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
ATE510558T1 (de) Verwendung von biologisch aktivem hiv-1 tat, fragmenten oder derivaten davon, zur bestimmung und/oder aktivierung von antigen-präsentierenden zellen, und/oder zur abgabe von cargo-molekülen für impfung und/oder für behandlung von anderen erkrankungen
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
DE60140794D1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
PT891331E (pt) Derivados do acido n-(2-oxoacetil ou sulfonil)-pirrolidino/piperidina-2-carboxilico com actividade melhorada de resistencia a multifarmacos
BR0012528A (pt) Cobertura aperfeiçoada para feridas para melhorar a cicatrização de feridas
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE123814T1 (de) Gentechnologische menschliche cholinesterasen.
TR200100622T2 (tr) NAB1 ve NAB2'nin farmasötik kullanımları
TR199901385T2 (tr) Piperidin türevleri.
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
TR199902866T2 (tr) Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlari, hazirlanmalari ve terapide kullanilmalari için prosesler.
ATE540968T1 (de) Alpha-fetoproteinpeptide und deren verwendungen
TR200102265T2 (tr) Anestezi düzenlemesi.
PT1115375E (pt) Utilizacao de pelo menos um derivado do acido 10-hidroxi-2-decenoico numa composicao destinada a favorecer a descamacao da pele
EP1083927A4 (en) PROTEIN YOUNG HUMAN VOUTE p193
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2000026362A3 (de) Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie